Vast Therapeutics, Inc announced that Chuck Swoboda has joined the company as President & CEO. Prior to joining the company, he spent more than 25 years at Cree, Inc, where he helped lead the company from $6 million in revenue to over $1.6 billion. During his 16 years as Cree CEO, the company was recognized as one of MIT Technology Review's 50 Smartest Companies and as one of Fast Company's World's 50 Most Innovative Companies.
About Vast Therapeutics, Inc.
Vast Therapeutics, a subsidiary of KNOW Bio, LLC, a preclinical stage biotechnology company, focused on harnessing nitric oxide's unique properties to treat drug-resistant microbial infections. Vast Therapeutics' patented technology is being used to create a new class of antibiotic alternative compounds that deliver broad-spectrum antimicrobial activity without the risk of developing drug resistance common to traditional antibiotics. More info available at www.vasttherapeutics.com.
Comments are closed.